Aktis Oncology: Takeaways from our investor dinner with Aktis Oncology management

Research evidence excerpt

Aktis Oncology: Takeaways from our investor dinner with Aktis Oncology management

Accessible version

Aktis Oncology

Takeaways from our investor dinner with

Aktis Oncology management

Maintain Rating: BUY | PO: 34.00 USD | Price: 19.53 USD

Miniproteins boast attractive qualities for radiopharma 15 May 2026

We hosted an investor dinner with AKTS management and came away with incremental Equity

appreciation for the platform rationale, lead program positioning, and

Alec W. Stranahan

manufacturing/supply chain execution as potential differentiators in radiopharma. Research Analyst

Management framed the core strategy as extending radiopharmaceutical benefit into BofAS alec.stranahan@bofa.com

tumors with limited approved options, leveraging a miniprotein platform intended to

Matthew Guggenbiller

combine antibody-like selectivity with peptide-like pharmacology. The key design Research Analyst

principle is rapid systemic clearance, with expected circulating half-life of ~2-3 hours, BofAS matthew.guggenbiller@bofa.com

while preserving tumor uptake and dwell time; management argued this profile is

particularly well suited to radiopharma, where durable exposure is less important than

upfront tumor debulking and localized radiation delivery. Reiterate Buy, $34 PO.

Stock Data

Quick screening, exclusivity benefits of miniproteins

Price 19.53 USD

On the platform, AKTS emphasized that miniproteins are among the shortest

Price Objective 34.00 USD

polypeptides capable of folding into a 3D structure, are typically ~30-60 amino acids in

Date Established 3-Feb-2026

length, and are materially smaller than antibody fragments. Management highlighted

Investment Opinion C-1-9

that the smaller size enables synthetic manufacturing and fine-tuning of properties,

52-Week Range 14.72 USD - 29.16 USD